<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00639496</url>
  </required_header>
  <id_info>
    <org_study_id>7112LAMC01</org_study_id>
    <nct_id>NCT00639496</nct_id>
  </id_info>
  <brief_title>Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF)</brief_title>
  <acronym>IFIGENIA</acronym>
  <official_title>Idiopathic Pulmonary Fibrosis International Group Exploring NAC I Annual Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zambon SpA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zambon SpA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether NAC added to prednisone, and azathioprine
      has a better effect on lung function, radiology and clinical condition than placebo +
      prednisone in combination with azathioprine after 6 and 12 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2000</start_date>
  <completion_date type="Actual">July 2003</completion_date>
  <primary_completion_date type="Actual">July 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vital capacity (VC) and diffusion capacity for CO (DLCO)</measure>
    <time_frame>at 6 and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical, radiologic and physiologic (CRP)-score</measure>
    <time_frame>at 6 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">184</enrollment>
  <condition>Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients taking NAC 600 mg t.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>n-acetylcysteine</intervention_name>
    <description>600 mg x 3, for 12 months</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Flumucil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of IPF according to the International Consensus Statement

          -  Bronchoalveolar lavage (BAL) showing no features to support an alternative diagnosis.

          -  Patients in whom it was possible to determine single breath DLco.

          -  Patients with newly or previously diagnosed IPF, in whom it was clinically justified
             to use the standardised regimen azathioprine plus prednisone

        Exclusion Criteria:

          -  Known intolerance to N-Acetylcysteine.

          -  Patients with respiratory infections at study entry should be excluded until the
             infections have been treated successfully (VC and Dlco comparable with the values
             before the infection).

          -  Patients with pre-existing disease that interferes with the evaluation of IPF:
             extensive old TBC lesions, significant bronchiectasis, moderate or severe COPD.

          -  Patients with malignancy in the last 5 years. If the patient had a malignancy in the
             past and is free of malignancy for more than five years, the patient is regarded as
             healed.

          -  Patients with heart failure.

          -  Patients with hepatic function abnormalities contraindicating the use of azathioprine
             (i.e. clinically significant abnormalities of PTT and/or GGT).

          -  Patients with a renal clearance &lt; 10ml/min and/or hematuria and/or proteinuria of
             collagen vascular disease origin. A renal clearance is only performed in the presence
             of an abnormal serum creatinine and/or serum urea level.

          -  Patients who are artificially ventilated.

          -  Prednisone at a dose &gt; 0.5 mg/kg/day (or other glucocorticoids such as triamcinolone,
             dexamethasone or methylprednisolone at an equivalent dose) or azathioprine at a dose &gt;
             2 mg/kg/day during the last month prior to inclusion.

          -  Use of other immunosuppressives (such as cyclophosphamide and colchicine) is not
             allowed in the last month and for the duration of the trial.

          -  Any form of anticancer therapy or methotrexate are not allowed when used for more than
             1 week in the past and for the duration of the trial.

          -  Amiodarone or nitrofurantoin are not allowed in the last 5 years, when used for more
             than 1 week in the past and for the duration of the trial.

          -  Allopurinol, oxypurinol, thiopurinol, anti-oxidants (e.g. vitamin E) or glutathione
             supplements are not allowed in the last month and during the trial.

          -  The use of interferon or other antifibrotics (e.g. pirfenidone) is not allowed in the
             past and during the study.

          -  The use of NAC therapy at a dosage of more than 600 mg/day is not allowed in the last
             3 years for a total period of more than 3 months.

          -  Patients suffering or having suffered from documented active ulcer within the last 3
             years.

          -  Patients in whom the standardised treatment regimen is contraindicated or not
             justified.

          -  Pregnancy.

          -  Known or suspected drug or alcohol abuse.

          -  Patients on other investigational compounds or participating in clinical trials on
             investigational compounds within the last 3 months.

          -  Patients expected to be non-compliant in taking the medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Demedts, MD</last_name>
    <role>Study Chair</role>
    <affiliation>U.Z.-Gasthuisberg, Leuven, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.Z. Ghent</name>
      <address>
        <city>Gent</city>
        <zip>B- 9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital A. Calmette</name>
      <address>
        <city>Lille Cedex</city>
        <zip>F 59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Grosshadern</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. di Pneumologia-Ospedale</name>
      <address>
        <city>Arezzo</city>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stichting St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Edinburgh-Medical School</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH8 9AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Capron F, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Corvasce G, Lankhorst I, Sardina M, Montanari M; IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005 Nov 24;353(21):2229-42.</citation>
    <PMID>16306520</PMID>
  </results_reference>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2008</study_first_submitted>
  <study_first_submitted_qc>March 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2008</study_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idiopathic Pulmonary Fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

